Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) will discontinue clinical development of Ace-ER after disappointing Phase 3 study results. The stock price plunged $7.83 to close at $51.02.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Home | News | Travel | Restaurants | Nightlife | Things To Do | Shopping | Calendar | Directory | Real Estate | Blog | More
|